On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- MHLW Committee Compiles Discussion Points on System for Public Release of Drug Damage Documents
June 20, 2012
- MHLW Withdraws Orphan Drug Designation for Somatropin
June 18, 2012
- MHLW Designates 5 Products, Including CLL Treatment, as Orphan Drugs
June 18, 2012
- DPJ Approves Draft Bill to Establish 3rd-Party Organization; Will Seek Discussions with Opposition
June 18, 2012
- Developed or Developing Countries: Which Side Is Right on Humanitarian Aid?
June 18, 2012
- MHLW Selects Kitasato Univ. Hospital, FBRI as Base for Japan-Led Global Clinical Research
June 15, 2012
- Mr Umemura of DPJ Proposes Obligatory Use of Generics for Welfare Recipients
June 15, 2012
- MHLW Study Group Might Postpone Concrete Conclusion on Relief System for Victims of Health Damage Due to Anticancer Drugs
June 13, 2012
- Ryukaikon’s Working Team Prepares to Start Operations by End of June; Beginning with Exchange of Opinions between JPWA, NPhA
June 13, 2012
- With Consumption Tax Hike in 2015, “Focus on Whether to Conduct Market Price Survey”: EAD Director Kamata
June 12, 2012
- PAFSC Committee Gives Green Light to OTC Switching of Hyaluronate Sodium
June 11, 2012
- Committee on Non-Prescription Drugs Recommends Approval for Switch OTC Versions of Allegra
June 11, 2012
- Medical Community Expresses Caution on Deferment of Experimental Animal Regulations by DPJ
June 8, 2012
- Gov’t Council Finalizes 5-Year Medical Innovation Strategy Calling for Creation of Drug Discovery Support Network
June 8, 2012
- Expert Subcommittee Begins Discussions on Pricing of Long-Listed Drugs with Focus on Differences from Generic Prices
June 8, 2012
- Drug Cost Ratio in FY2009 was 22.3%, Up 1.1 Points from Previous Year: MHLW
June 8, 2012
- Local Governments Express Concern for IPV Price at 5,450 Yen
June 7, 2012
- Survey Highlights Successful Efforts of 5 Prefectures to Promote Generic Drug Use
June 6, 2012
- PAFSC 1st Committee on New Drugs Recommends Approval for Fibromyalgia Indication for Lyrica
June 5, 2012
- DPJ’s Proposal on 5-Year Innovation Strategy Calls for Subsidies to Reduce Consultation, Review Fees
June 4, 2012
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…